Dr. Anan Chongkaewwatana, virologist Director of Animal Health and Management Innovation Research Group National Center for Genetic Engineering and Biotechnology (Biotech), National Science and Technology Development Agency (NSTDA) posted a message via Facebook Anan Jongkaewwattana stated that…
The first Lot of GMP-level COVID-19 vaccine generated from influenza-based influenza virus particles has been produced by the GMP research team. It is important to register the vaccine for testing in humans. This is the second vaccine for the NSTDA team. The one that will come out to test before will be Adenovirus-based which has been tested for safety in laboratory animals…Both vaccines are designed as nasal spray…Product of Team Thailand
